1 - Carol Davila Central Emergency Military Hospital, Bucharest
2 - C.I. Parhon National Institute of Endocrinology, Bucharest
3 - Carol Davila University of Medicine and Pharmacy, Faculty of Medicine, Bucharest
Received: October 30, 2014
Accepted: December 15 2014.
Paraneoplastic Cushing syndrome represents 5-10%
of all Cushing syndrome and has a severe prognosis
due to severe metabolic imbalance, denutrition,
associated infections and progression of tumoral
underlying pathology. The death is a rule in more
than 50% of cases. Some medication used to treat it –
Metirapone – is not available in Romania.
Ketoconazole was recently approved by CHMP for
treatment of paraneoplastic Cushing’s only in
November 2014.
Mazilu, A., Gheorghiu, M., Musat, M., Tanase, N., Petrescu, R., Ciuche, A., Tudose, A., & Vasilescu, F. (2025). Paraneoplastic cushing’s syndrome in a patient with multiple tumors – case report. Romanian Journal of Military Medicine, 118(1), 34-37.
Mazilu A, Gheorghiu M, Musat M, Tanase N, Petrescu R, Ciuche A, et al. Paraneoplastic Cushing’s Syndrome in a patient with multiple tumors – case report. Rom J Mil Med. 2025;118(1):34-37.
Mazilu, A., Gheorghiu, M., Musat, M., Tanase, N., Petrescu, R., Ciuche, A., Tudose, A. & Vasilescu, F. 2025, 'Paraneoplastic Cushing’s Syndrome in a patient with multiple tumors – case report', Romanian Journal of Military Medicine, vol. 118, no. 1, pp. 34-37.
